Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 1441-1450 Newer>

The Motley Fool March 30, 2004 Seth Jayson	CarMax Inches Forward CarMax turns out solid numbers, but are its shares worth the going price?
The Motley Fool March 30, 2004 Brian Gorman	Sara Lee's Coffee Crusade The company's plan to buy coffee grown using sustainable methods is good for business.
The Motley Fool March 30, 2004 David Nierengarten	Jumping Biotechs A cancer research conference drives smaller biotechs higher.
The Motley Fool March 30, 2004 Seth Jayson	Is J2's Punishment Justified? J2 is on a run. So why the cold shoulder from the Street? Shares of J2 Global Communications are 55% above their 52-week low -- but are still 57% off the year's high of almost $48.
The Motley Fool March 30, 2004 Rick Aristotle Munarriz	SportsLine.com's Blocked Shot It may be SportsLine.com's season, but an SEC investigation puts a damper on team spirit.
The Motley Fool March 30, 2004 Rick Aristotle Munarriz	California Dreamy California Pizza Kitchen knows how to work its toppings. It posted healthy gains at the store level and raised its profit outlook.
The Motley Fool March 30, 2004 Charly Travers	Genentech: Priced for Perfection Can Genentech's earnings growth keep up with its valuation? The launch of three new products in the last nine months has made Genentech a very popular, and expensive, company.
BusinessWeek April 5, 2004 Joseph Weber	A Dividend Windfall In The Corner Office Following the White House's move to cut the tax on dividends from 35% to 15%, many companies have boosted payouts sharply. Where execs and directors have big holdings, that means the same folks who voted in the hefty payouts will be among the largest beneficiaries.
BusinessWeek April 5, 2004 David Fairlamb	Selling Off Germany Inc. Unraveling Germany Inc. has allowed Allianz to reinvest the money in its core businesses and to shore up its standing with rating agencies by reducing its exposure to volatile equities.
The Motley Fool March 29, 2004 W.D. Crotty	OraSure Not That Sure Its oral-fluid HIV test is a breakthrough, but the stock isn't cheap.
<Older 1441-1450 Newer> Return to current articles.